RouseRKruhlakNWeaverJet al.Translating new science into the drug review process: the US FDA’s Division of Applied Regulatory Science. Therapeutic Innovation & Regulatory Science. 2018;52:244–255.
2.
Tan-KoiWCLeowPCTeoYY. Applications of pharmacogenomics in regulatory science: a product life cycle review. Pharmacogenomics J. 2018;18:359–366.
3.
International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use. www.ich.org(accessed July 7, 2019).
TörnqvistEAnnasAGranathBet al.Strategic focus on 3 R principles reveals major reductions in the use of animals in pharmaceutical toxicity testing. PLoS One. 2014;9:e101638.
6.
AskeKCWaughCA. Expanding the 3 R principles: more rigour and transparency in research using animals. EMBO Rep. 2017;18:1490–1492.
7.
FrancoNHSandøePOlssonIAS. Researchers’ attitudes to the 3Rs—an upturned hierarchy?PLoS One. 2018;13(8):e0200895.
8.
SatinLZDurhamTATurnerJR. Assessing a drug’s proarrhythmic liability: an overview of computer simulation modeling, nonclinical assays, and the Thorough QT/QTc Study. Drug Info J. 2011:45;357–375.
9.
TurnerJRKarnadDRCabellCHKothariS. Recent developments in the science of proarrhythmic cardiac safety of new drugs. Eur Heart J Cardiovasc Pharmacother. 2017;3:118–124.
10.
TurnerJRRodriquezIMantovaniEet al; on behalf of the Cardiac Safety Research Consortium. Drug-induced proarrhythmia and torsade de pointes: a primer for students and practitioners of medicine and pharmacy. J Clin Pharmacol. 2018;58:997–1012.
11.
VicenteJStraussDGUpretiVVet al.The potential role of the J-Tpeak interval in proarrhythmic cardiac safety: current state of the science from the American College of Clinical Pharmacology and the Cardiac Safety Research Consortium. J Clin Pharmacol. 2019;59:909–914.
12.
VlachosKGeorgopoulosSEfremidisMSiderisALetsasKP. An update on risk factors for drug-induced arrhythmias. Expert Rev Clin Pharmacol. 2016;9:117–127.
13.
VandaelEVandenberkBVandenbergheJWillemsRFoulonV. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39:16–25.
SagerPTGintantGTurnerJRPettitSStockbridgeN. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J. 2014;167:292–300.
23.
GintantGSagerPTStockbridgeN. Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov. 2016;15:457–471.
24.
VicenteJZusterzeelRJohannesenLet al.Mechanistic model-informed proarrhythmic risk assessment of drugs: review of the “CiPA” Initiative and design of a prospective clinical validation study. Clin Pharmacol Ther. 2018;103:54–66.
25.
WallisRBensonCDarpoBet al.CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion. J Pharmacol Toxicol Methods.2018;93:15–25.
26.
VicenteJ. Update on the ECG component of the CiPA initiative. J Electrocardiol. 2018;51(6 suppl): S98–S102.
